Synopsis Migraine is the most common and debilitating brain disorder characterized by painful and throbbing headaches with or without aura for almost 15 days per month. Patients with chronic migraines who present to a primary healthcare setup are often referred for secondary care management. Most patients with chronic migraines have been reported to overuse medications like analgesics, opioids, triptans, or ergot derivatives on at least ten days per month. Fremanezumab is a fully-humanized monoclonal antibody. The drug selectively targets calcitonin gene-related peptide.
The FDA approved indication of this drug is mainly for the treatment of migraine in adults. This “Journal Watch” discusses a research study from “Neurology” titled “Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine,” Aug 2020. Authors: Richard B. Lipton, Joshua M. Cohen et.al…
